low-density lipoprotein

low-density lipoprotein
Name	Low-density lipoprotein
Caption	Schematic representation
Type	Lipoprotein particle
Density	1.019–1.063 g/mL
Diameter	18–25 nm
Main component	Apolipoprotein B-100, cholesterol esters, phospholipids

low-density lipoprotein is a class of plasma lipoprotein particles involved in lipid transport that plays a central role in cardiovascular biology, human pathology, and clinical medicine. It is biochemically characterized by a core of cholesterol esters and a surface monolayer containing apolipoprotein B-100, and its concentrations have been linked to risk stratification in major public health initiatives and clinical guidelines. Research on this particle involves collaborations among institutions such as National Institutes of Health, World Health Organization, American Heart Association, and laboratories at universities like Harvard University and University of Oxford.

Structure and composition

The particle contains a hydrophobic core of cholesterol esters and triglycerides surrounded by a surface monolayer of phospholipids, unesterified cholesterol, and a single molecule of apolipoprotein B-100, a large glycoprotein encoded by the APOB gene studied at centers including Johns Hopkins University and Mayo Clinic. Structural models derive from techniques pioneered by facilities such as the European Molecular Biology Laboratory and the Max Planck Society, and integrate data from cryo-electron microscopy used at the Cold Spring Harbor Laboratory and X-ray studies from the Rutherford Appleton Laboratory. Comparative lipidomics linking to studies at Columbia University and Stanford University reveal species- and disease-specific variations; for example, alterations in phosphatidylcholine content reported by researchers at Massachusetts Institute of Technology and Karolinska Institutet.

Synthesis, metabolism, and transport

LDL particles originate from the metabolic processing of very low-density lipoprotein (VLDL) secreted by hepatocytes in the liver, a process characterized in investigations at Imperial College London and University College London. Enzymatic steps involve lipoprotein lipase and hepatic lipase activities described in classic work at institutions like University of Cambridge and Yale University. Receptor-mediated uptake of LDL via the LDL receptor, whose mutations were identified by research teams at University of Texas Southwestern Medical Center and Fred Hutchinson Cancer Center, is central to clearance; defects in this pathway underlie familial hypercholesterolemia described in cohorts followed at Cleveland Clinic and Baylor College of Medicine. Intracellular cholesterol trafficking engages organelles studied at Max Planck Institute for Molecular Cell Biology and Genetics and signaling networks linked with National Cancer Institute investigations.

Physiological roles

LDL serves as the principal circulating carrier delivering cholesterol to peripheral tissues, a function elucidated by physiology groups at University of Chicago and University of Pennsylvania. Cholesterol provided by LDL is used for membrane biogenesis, steroidogenesis in endocrine organs such as the Mayo Clinic endocrine division and mitochondrial function researched at University of California, San Francisco. In the immune context, LDL interactions with macrophages and dendritic cells have been characterized in work at Salk Institute and Rockefeller University, where lipid antigen presentation and inflammatory modulation were explored. Population health implications of LDL concentrations inform policy discussions at Centers for Disease Control and Prevention and guideline panels at the European Society of Cardiology.

Pathophysiology and atherosclerosis

Elevated circulating LDL is causally linked to the development of atherosclerotic plaques, a process extensively studied by investigators at Mount Sinai Health System, Karolinska University Hospital, and University of Melbourne. Oxidative modification of LDL and subendothelial retention mediated by proteoglycans were described in landmark studies from Weill Cornell Medicine and Johns Hopkins Hospital, while translational imaging of plaque progression has been advanced by collaborations with Mayo Clinic and Cleveland Clinic. Genetic contributors to LDL-related disease risk include loci identified by genome-wide association consortia at Wellcome Trust Sanger Institute and Broad Institute, informing precision medicine approaches tested in trials run by institutions like Duke University and University of Oxford.

Clinical measurement and interpretation

Clinical laboratories measure LDL cholesterol using direct assays or calculation methods such as the Friedewald equation developed by researchers associated with University of Minnesota and validated in cohorts at Framingham Heart Study. Interpretation of LDL values is guided by risk algorithms and guidelines from organizations including the American College of Cardiology, American Heart Association, and National Institute for Health and Care Excellence. Epidemiological links between LDL levels and outcomes derive from landmark trials and cohort studies coordinated by groups at Intermountain Healthcare, Johns Hopkins Bloomberg School of Public Health, and multinational studies funded by the European Commission.

Therapeutic interventions and guidelines

Therapeutic lowering of LDL is a cornerstone of cardiovascular prevention, with statins pioneered in clinical trials conducted at Imperial College London and University of Oxford, PCSK9 inhibitors developed through collaborations between industry and academia including Amgen and Regeneron and tested in large-scale trials coordinated with centers like Brigham and Women's Hospital. Other interventions, such as ezetimibe evaluated at University of Glasgow and bile acid sequestrants studied at University of California, Los Angeles, complement lipid-lowering strategies. Current guideline implementation and health-system level strategies are informed by policy bodies including the World Health Organization, European Society of Cardiology, and American Heart Association, and are applied in clinical networks such as NHS England and the Veterans Health Administration.

Category:Lipoproteins